PBE.US Invesco Dynamic Biotechnology & Genome ETF
- Total assets
- 438M
- Expense ratio
- 0.58%
- Dividend yield
- 1.30%
- 1-year return
- +31.78%
- Holdings
- 31
- Since
- 2005
Fund data as reported by the issuer, updated Nov 15, 2026. Total assets are in the fund's base currency.
What does PBE.US invest in?
- Mostly US stocks (99.2%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (100.0%)
- Top 3 holdings: 17.0% of the fund
Asset allocation
- US stocks 99.2%
- Cash 0.0%
Top holdings
- Regeneron Pharmaceuticals Inc 5.76%
- Biogen Inc 5.64%
- Gilead Sciences Inc 5.64%
- Royalty Pharma Plc 5.51%
- Amgen Inc 5.37%
Invesco Dynamic Biotechnology & Genome ETF performance
Sharpe ratio 1.25- This year
- +23.56%
- 1 year
- +31.78%
- 3 years
- +23.03%
- 5 years
- +7.05%
Volatility 16.0% over 1 year and 16.5% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
PBE.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About Invesco Dynamic Biotechnology & Genome ETF
Under normal circumstances, at least 80% of the value of its net assets, plus the amount of any borrowings for investment purposes, in securities of companies engaged in biotechnology- and genome-related industries, and in derivatives and other investments that have economic characteristics similar to securities of companies engaged in biotechnology- and genome-related industries (the "80% investment policy"). It is non-diversified.
Full fund profileInvesco Dynamic Biotechnology & Genome ETF top holdings
50.1% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc REGN.US | Healthcare | United States | 5.76% |
| Biogen Inc BIIB.US | Healthcare | United States | 5.64% |
| Gilead Sciences Inc GILD.US | Healthcare | United States | 5.64% |
| Royalty Pharma Plc RPRX.US | Healthcare | United States | 5.51% |
| Amgen Inc AMGN.US | Healthcare | United States | 5.37% |
| Natera Inc NTRA.US | Healthcare | United States | 4.93% |
| Vertex Pharmaceuticals Inc VRTX.US | Healthcare | United States | 4.92% |
| Illumina Inc ILMN.US | Healthcare | United States | 4.57% |
| Moderna Inc MRNA.US | Healthcare | United States | 4.01% |
| Vericel Corp Ord VCEL.US | Healthcare | United States | 3.79% |
The 10 largest of 31 holdings.
PBE.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
PBE.US regional exposure
- North America100.0%
Share of the stocks in the fund.
Company size
Average market cap 19.2B- Big cap21.8%
- Medium cap33.9%
- Small cap22.9%
- Micro cap19.9%
Invesco Dynamic Biotechnology & Genome ETF fund profile
- Fund name
- Invesco Dynamic Biotechnology & Genome ETF
- Ticker
- PBE.US
- Exchange
- USA Stocks
- Issuer
- Invesco
- Index tracked
- -
- Category
- Healthcare Equity
- Domicile
- United States
- Inception date
- Jun 23, 2005
- Trading currency
- USD
- Expense ratio
- 0.58%
- Annual turnover
- 0.7%
About Invesco Dynamic Biotechnology & Genome ETF
Under normal circumstances, at least 80% of the value of its net assets, plus the amount of any borrowings for investment purposes, in securities of companies engaged in biotechnology- and genome-related industries, and in derivatives and other investments that have economic characteristics similar to securities of companies engaged in biotechnology- and genome-related industries (the "80% investment policy"). It is non-diversified.